Marshall Wace
ORMP icon

Marshall Wace’s Oramed Pharmaceuticals ORMP Stock Holding History

Marshall Wace’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
101,953
-157,658
-61% -$628K ﹤0.01% 2532
2026
Q1 		$883K Buy
259,611
+556
+0.2% +$1.89K ﹤0.01% 2201
2025
Q4 		$738K Buy
+259,055
New +$668K ﹤0.01% 2078
2024
Q4 		– Sell
-22,527
Closed -$55K – 2898
2024
Q3 		$55K Buy
+22,527
New +$54.9K ﹤0.01% 2414
2023
Q2 		– Sell
-10,553
Closed -$23K – 2836
2023
Q1 		$23K Sell
10,553
-26,846
-72% -$85.3K ﹤0.01% 2568
2022
Q4 		$450K Buy
37,399
+8,990
+32% +$69.9K ﹤0.01% 2413
2022
Q3 		$185K Buy
28,409
+8,900
+46% +$72K ﹤0.01% 3100
2022
Q2 		$90K Buy
+19,509
New +$104K ﹤0.01% 3289
2021
Q2 		– Sell
-11,563
Closed -$117K – 2962
2021
Q1 		$117K Sell
11,563
-25,069
-68% -$206K ﹤0.01% 2345
2020
Q4 		$155K Sell
36,632
-22,016
-38% -$71.6K ﹤0.01% 1771
2020
Q3 		$153K Buy
58,648
+10,388
+22% +$36.2K ﹤0.01% 1489
2020
Q2 		$170K Sell
48,260
-29,101
-38% -$97.7K ﹤0.01% 1432
2020
Q1 		$235K Sell
77,361
-36,345
-32% -$159K ﹤0.01% 1153
2019
Q4 		$586K Buy
+113,706
New +$426K ﹤0.01% 1122

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's ORMP Position: Q2 2026 in Review

Marshall Wace reduced its Oramed Pharmaceuticals (ORMP) stake by 61% in Q2 2026, selling an estimated $628K and leaving 101,953 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Marshall Wace first reported a position in ORMP in Q4 2019 and has held it in 14 quarters since. The position peaked at $883K in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Marshall Wace held 101,953 shares of Oramed Pharmaceuticals worth $490K as of Q2 2026.
  • Marshall Wace sold 157,658 Oramed Pharmaceuticals shares in Q2 2026, an estimated $628K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2532 holding.
  • Marshall Wace first reported a position in Oramed Pharmaceuticals in Q4 2019 and has held it in 14 quarters since.
  • Marshall Wace's Oramed Pharmaceuticals position peaked at $883K in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.